RESUMO
Objectives: To assess the impact of all-oral direct-acting antiviral agent (DAA) regimens on the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients with cirrhosis. Methods: This was a multicentre prospective cohort study recruiting HIV/HCV-coinfected patients with a new diagnosis of compensated cirrhosis. Patients were followed up until HCC, death or the censoring date (March 2017). The primary endpoint was the emergence of HCC. The incidence rate (IR) (95% CI) of HCC in different groups was computed. Time-to-event analyses were performed to identify predictors of HCC emergence. Results: The study included 495 HIV/HCV-coinfected patients with cirrhosis. After a median (IQR) follow-up of 59 (27-84) months, 22 (4.4%; 95% CI 2.6-6.3) patients developed an HCC. The IR (95% CI) of HCC was 0.93 (0.06-1.42) per 100 person-years (PY). Three hundred and three (61%) patients achieved sustained virological response (SVR) during follow-up, 79 after interferon (IFN)-based regimens and 224 after an all-oral DAA regimen. The IR (95% CI) of HCC after all-oral DAA was 0.35 (0.14-0.85) per 100 PY whereas it was 1.79 (1.11-2.88) per 100 PY in the remaining cohort (P = 0.0005). When only patients with SVR were considered, the IR (95% CI) of HCC after all-oral DAA was 0.32 (0.12-0.86) whereas it was 0 per 100 PY among those with SVR after IFN-based therapies (P = 0.27). Achieving SVR with an all-oral DAA regimen during follow-up was independently associated with a lower risk of HCC emergence (subhazard ratio 0.264; 95% CI 0.070-0.991; P = 0.049). Conclusions: SVR with all-oral DAA regimens reduces the risk of HCC in HIV/HCV-coinfected patients with compensated cirrhosis.
Assuntos
Antivirais/uso terapêutico , Carcinoma Hepatocelular/prevenção & controle , Infecções por HIV/complicações , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Cirrose Hepática/complicações , Cirrose Hepática/tratamento farmacológico , Adulto , Coinfecção/complicações , Coinfecção/tratamento farmacológico , Feminino , Seguimentos , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Medição de Risco , Resposta Viral SustentadaRESUMO
We studied hepatic steatosis in people with HIV (PWH) who switched to an integrase inhibitor (INSTI)-based regimen. One hundred and fifty-four PWH were included. After 48âweeks, median (Q1-Q3) weight gain was 1.2 (-0.6 to 3.8) kg and median (Q1-Q3) controlled attenuation parameter (CAP) change was -4 (-33 to 27) dB/m. Weight gain was weakly correlated with CAP change [R2 95% confidence interval (CI)â=â0.144 (-0.014 to 0.296); Pâ=â0.074)]. Changes in hepatic steatosis after switching to INSTI-based regimens do not seem to parallel weight gain after 1 year.
Assuntos
Técnicas de Imagem por Elasticidade , Fígado Gorduroso , Infecções por HIV , Inibidores de Integrase de HIV , Humanos , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Inibidores de Integrase de HIV/efeitos adversos , Aumento de PesoRESUMO
OBJECTIVES: To assess HAV serologic and vaccination status among people who live with HIV (PLWH), and to evaluate the impact of a vaccination-based strategy on HAV-negative patients in Seville, Spain. METHODS: Study with two time-overlapping phases: (i) cross-sectional study of HAV immunity prevalence among PLWH followed at a Spanish hospital between August 2019 and March 2020. (ii) Patients seronegative for HAV, reliably unvaccinated were included in a before-and-after quasi-experimental study, with an intervention focused on HAV vaccination according to national recommendations in force. RESULTS: Six hundred and fifty-six patients were included, of which 111 [17%, 95% confidence interval (95% CI) 14-20%] were seronegative for HAV. Of these, 48 [43% (95% CI, 34-53%)] individuals were MSM. The absence of HAV immunity was attributed in 69 [62% (95% CI, 52-71%)] patients to non-referral to vaccination, followed by lack of achievement of a correct vaccination scheme [n=26; 23% (95% CI, 16-32%)]. After the program implementation, 96 [15% (95% CI, 12-18%)] individuals were seronegative (17% vs. 15%, p=0.256), of whom 42 [41% (95% CI, 32-51%)] were MSM. The absence of immunity after the intervention was mainly attributed to: adherence failure in 23 [24.0% (95% CI, 15.8-33.7%)] patients, on-course immunization scheme in 34 [33% (95% CI, 24-43%)] individuals and pending appointment at the vaccine delivery unit in 20 [20.8% (95% CI, 13.2-30.3%)] patients. CONCLUSIONS: A sizeable proportion of PLWH remains susceptible for HAV infection in future outbreaks. A program based on referral to the vaccine delivery unit yields poor results, largely due to program adherence failures. New strategies are needed to increase HAV vaccination coverage.
Assuntos
Infecções por HIV , HIV , Humanos , Cobertura Vacinal , Estudos Transversais , ImunizaçãoRESUMO
BACKGROUND: Periodic outbreaks of hepatitis A (HAV) infection in men who have sex with men (MSM) have been reported. Low vaccination uptake in HIV-infected individuals could drive new outbreaks. We aimed at evaluating the incidence of and risk factors for HAV infection in people living with HIV (PLWH) in our area. We also assessed the rates of HAV vaccination. METHODS: This was a prospective cohort study. 915 patients were included, 272 (30%) of them were anti-HAV seronegative at baseline. RESULTS: Twenty-six (9.6%) susceptible individuals became infected. Incident cases peaked in 2009-2010 and 2017-2018. Incident HAV infection was independently associated with MSM [adjusted odds ratio (95% confidence ratio): 4.39 (1.35-14.27), p=0.014]. One hundred and five (38.6%) HAV seronegative patients were vaccinated, 21 (20%) of them did not respond, and one (1%) patient lost immunity against HAV. Four (29%) non-responders to vaccination showed incident HAV 5-9 years afterwards. CONCLUSIONS: The incidence of HAV infection in a cohort of well-controlled PLWH remains low and stable, with intermittent outbreaks involving mainly non-immunized MSM. A significant proportion of PLWH remain susceptible to HAV infection due to insufficient vaccine uptake and limited response to vaccination. Importantly, patients not responding to HAV vaccination continue at risk of infection.
RESUMO
Whether people living with HIV (PLWH) are at greater risk of acquiring SARS-CoV-2 infection is currently unknown. Prospective serologic studies may allow seroincidence analyses, where all infections are accurately identified. Because of this, we evaluated the incidence of associated factors with and the clinical outcome of SARS-CoV-2 infection in PLWH in Southern Spain. This prospective cohort study included PLWH from a Tertiary University Hospital in Southern Spain. Patients were enrolled in the study if (1) they had attended as outpatients our Unit from 1 August 2019 to 8 February 2020 and (2) had two subsequent evaluations from 9 February 2020 to 4 March 2021. SARS-CoV-2 infections were diagnosed by PCR, antigen detection or serology. Seven hundred and nine PLWH were included in the study. Of them, 55 [7.8%, 95% confidence interval (95% CI) 5.9%-9.9%] patients developed SARS-CoV-2 infection. Between 18 May and 29 November 2020, the rate of seroconversion was 5.3% (95% CI: 3.1%-9.0%) for the general population in the area of Seville and 2.3% (95% CI: 1.3%-2.6%) for PLWH in this study (p = .001). After multivariable analysis, adjusted by age, sex, and risk factors for HIV infection, active tobacco use and CDC stage, active tobacco smoking was the only factor independently associated with lower risk of SARS-Cov-2 infection [Incidence rate ratio: 0.29 (95% CI 0.16-0.55) p < .001]. In conclusion, the incidence of SARS-CoV-2 infection among PLWH in Southern Spain during the ongoing pandemic was lower than that reported for the general population in the same area.
Assuntos
COVID-19 , Infecções por HIV , Animais , COVID-19/epidemiologia , COVID-19/veterinária , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Infecções por HIV/veterinária , Humanos , Incidência , Pandemias , Estudos Prospectivos , SARS-CoV-2 , Espanha/epidemiologiaRESUMO
The diagnosis of non-alcoholic steatohepatitis (NASH) requires liver biopsy. Patients with NASH are at risk of progression to advanced fibrosis and hepatocellular carcinoma. A reliable non-invasive tool for the detection of NASH is needed. We aimed at developing a tool to diagnose NASH based on a predictive model including routine clinical and transient hepatic elastography (TE) data. All subjects undergoing elective cholecystectomy in our center were invited to participate, if alcohol intake was < 30 g/d for men and < 15 g/d for women. TE with controlled attenuation parameter (CAP) was obtained before surgery. A liver biopsy was taken during surgery. Multivariate logistic regression models to predict NASH were constructed with the first 100 patients, the elaboration group, and the results were validated in the next pre-planned 50 patients. Overall, 155 patients underwent liver biopsy. In the elaboration group, independent predictors of NASH were CAP value [adjusted OR (AOR) 1.024, 95% confidence interval (95% CI) 1.002-1.046, p = 0.030] and HOMA value (AOR 1.847, 95% CI 1.203-2.835, p < 0.001). An index derived from the logistic regression equation to identify NASH was designated as the CAP-insulin resistance (CIR) score. The area under the receiver operating characteristic curve (95%CI) of the CIR score was 0.93 (0.87-0.99). Positive (PPV) and negative predictive values (NPV) of the CIR score were 82% and 91%, respectively. In the validation set, PPV was 83% and NPV was 88%. In conclusion, the CIR score, a simple index based on CAP and HOMA, can reliably identify patients with and without NASH.
Assuntos
Técnicas de Imagem por Elasticidade , Resistência à Insulina , Neoplasias Hepáticas , Hepatopatia Gordurosa não Alcoólica , Masculino , Humanos , Feminino , Hepatopatia Gordurosa não Alcoólica/patologia , Técnicas de Imagem por Elasticidade/métodos , Fígado/patologia , Curva ROC , Biópsia , Neoplasias Hepáticas/patologia , Cirrose Hepática/patologiaRESUMO
Primary aim was to assess prevalence and severity of potential and real drug-drug interactions (DDIs) among therapies for COVID-19 and concomitant medications in hospitalized patients with confirmed SARS-CoV-2 infection. The secondary aim was to analyze factors associated with rDDIs. An observational single center cohort study conducted at a tertiary hospital in Spain from March 1st to April 30th. rDDIs refer to interaction with concomitant drugs prescribed during hospital stay whereas potential DDIs (pDDIs) refer to those with domiciliary medication. DDIs checked with The University of Liverpool resource. Concomitant medications were categorized according to the Anatomical Therapeutic Chemical classification system. Binomial logistic regression was carried out to identify factors associated with rDDIs. A total of 174 patients were analyzed. DDIs were detected in 152 patients (87.4%) with a total of 417 rDDIs between COVID19-related drugs and involved hospital concomitant medication (60 different drugs) while pDDIs were detected in 105 patients (72.9%) with a total of 553 pDDIs. From all 417 rDDIs, 43.2% (n = 180) were associated with lopinavir/ritonavir and 52.9% (n = 221) with hydroxychloroquine, both of them the most prescribed (106 and 165 patients, respectively). The main mechanism of interaction observed was QTc prolongation. Clinically relevant rDDIs were identified among 81.1% (n = 338) ('potential interactions') and 14.6% (n = 61) (contraindicated) of the patients. Charlson index (OR 1.34, 95% IC 1.02-1.76) and number of drugs prescribed during admission (OR 1.42, 95% IC 1.12-1.81) were independently associated with rDDIs. Prevalence of patients with real and pDDIs was high, especially those clinically relevant. Both comorbidities and polypharmacy were found as risk factors independently associated with DDIs development.
Assuntos
Tratamento Farmacológico da COVID-19 , Interações Medicamentosas , Hidroxicloroquina/química , Lopinavir/química , Ritonavir/química , Idoso , Analgésicos/química , Analgésicos/uso terapêutico , COVID-19/patologia , COVID-19/virologia , Doenças Cardiovasculares/tratamento farmacológico , Estudos de Coortes , Diuréticos/química , Diuréticos/uso terapêutico , Feminino , Humanos , Hidroxicloroquina/uso terapêutico , Lopinavir/uso terapêutico , Masculino , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/tratamento farmacológico , Polimedicação , Fatores de Risco , Ritonavir/uso terapêutico , SARS-CoV-2/isolamento & purificação , Índice de Gravidade de Doença , EspanhaRESUMO
Treatment guidelines differ in their recommendation to determine baseline resistance associated substitutions (RAS) before starting a first-line treatment with direct-acting antivirals (DAAs). Here we analyze the efficacy of DAA treatment with baseline RAS information. We conducted a prospective study involving 23 centers collaborating in the GEHEP-004 DAA resistance cohort. Baseline NS5A and NS3 RASs were studied by Sanger sequencing. After issuing a comprehensive resistance report, the treating physician decided the therapy, duration and ribavirin use. Sustained virological response (SVR12) data are available in 275 patients. Baseline NS5A RAS prevalence was between 4.3% and 26.8% according to genotype, and NS3 RASs prevalence (GT1a) was 6.3%. Overall, SVR12 was 97.8%. Amongst HCV-GT1a patients, 75.0% had >800,000 IU/ml and most of those that started grazoprevir/elbasvir were treated for 12 weeks. In genotype 3, NS5A Y93H was detected in 9 patients. 42.8% of the HCV-GT3 patients that started sofosbuvir/velpatasvir included ribavirin, although only 14.7% carried Y93H. The efficacy of baseline resistance-guided treatment in our cohort has been high across the most prevalent HCV genotypes in Spain. The duration of the grazoprevir/elbasvir treatment adhered mostly to AASLD/IDSA recommendations. In cirrhotic patients infected with GT-3 there has been a high use of ribavirin.
Assuntos
Hepacivirus/genética , Hepatite C Crônica/tratamento farmacológico , Proteínas não Estruturais Virais/genética , Amidas , Antivirais/efeitos adversos , Antivirais/uso terapêutico , Benzofuranos/uso terapêutico , Carbamatos , Ciclopropanos , Farmacorresistência Viral/genética , Feminino , Genótipo , Hepacivirus/patogenicidade , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/genética , Hepatite C Crônica/virologia , Humanos , Imidazóis/uso terapêutico , Masculino , Pessoa de Meia-Idade , Mutação , Quinoxalinas/uso terapêutico , Ribavirina/uso terapêutico , Sofosbuvir/uso terapêutico , Espanha/epidemiologia , Sulfonamidas , Resposta Viral SustentadaAssuntos
Hepacivirus/isolamento & purificação , Hepatite C/epidemiologia , Adulto , Estudos de Coortes , Coinfecção/epidemiologia , Coinfecção/virologia , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/virologia , Hepacivirus/fisiologia , Hepatite C/virologia , Homossexualidade , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Assunção de Riscos , Espanha/epidemiologiaRESUMO
Objetivo:Comparar la eficacia de parecoxib para el control del dolor postoperatorio de apendicectomias y colecistectomias en el servicio de recuperación y la menor necesidad de opioides con menos efectos secundarios en comparación con Diclofenac. Materiales y métodos: Por medio de un estudio cuaxiexperimental sin grupo control se comparó parecoxib con diclofenac en el control del dolor POP teniendo en cuenta variables como escala análoga visual, FC, TAM, dosis de morfina, tiempo de estancia en recuperación y efectos secundarios durante la permanencia en el servició de cuidados postanestésicos. Resultados: Se tuvieron en cuenta para el análisis estadístico 142 pacientes: 76 se les administró parecoxib y 66 diclofenac. La escala análoga visual de dolor, la FC y la TAM fue similar en ambos grupos de estudio, la dosis media de morfina utilizada fue de 4,6mg con parecoxib y 5,6 mg con diclofenac con una P 0.04 y un intervalo de confianza del 95 por ciento, no se encontraron diferencias significativas en los efectos secundarios ni en el tiempo medio de estancia en recuperación, el cual fue de 77min. Conclusiones: Para el manejo del dolor agudo con dosis única de cada medicamento no existen diferencias en cuanto a su efectividad y eficacia entre parecoxib y diclofenac en los dos tipos de cirugía practicadas...
Assuntos
Analgésicos , Analgésicos não Narcóticos , Analgésicos Opioides , Diclofenaco , Dor Pós-OperatóriaRESUMO
Las heridas son la principal causa de muerte en niños entre 1 y 14 años y producen incapacidad permanente a miles de ellos cada año. El trauma cerrado representa alrededor del 60 por ciento de las lesiones en la niñez. El trauma craneano es el mas común; pero los niños más severamente lesionados tienen compromiso multusistémico, frecuentemente de las extremidades, el tórax y el abdomen. La respuesta del niño a la injuria difiere de la del adulto y algunos patrones específicos se observan con el trauma cerrado; siendo su reconocimiento adecuado, esencial para su manejo
Assuntos
Humanos , Recém-Nascido , Lactente , Pré-Escolar , Criança , Assistência Perioperatória , Traumatismo Múltiplo/cirurgiaRESUMO
El presente estudio tiene como objetivo valorar la incidencia de parálisis residual neuromuscular en la unidad de cuidados intensivos en pacientes que reciben relajantes neuromusculares de acción intermedia en nuestra institución, por medio de la valoración de la función neuromuscular empleando tanto la relación TOF T4/T1 como el estímulo de doble ráfaga (DBS 3.2). Se tomaron 83 pacientes los males se distribuyeron en 2 grupos, Grupo A (Bromuro de rocuronio a dosis de 0.6 mgs/kg) Grupo B (Bromuro de vecuronio a dosis de 0.1 mg/ks), una vez el paciente fue admitido en la unidad de cuidados postanestésicos se realizó la valoración de la función neuromuscular por medio del monitor TOF-Watch, utilizando como parámetros de estudio, la relación TOF T4/T1 y el DBS 3.2. Se obtuvo una incidencia de parálisis residual en el grupo A de 13.3 por ciento en el grupo B de 5.3 por ciento por medio de valoración con DBS 3.2, mientras que al utilizar la relación TOF T4/T1 la incidencia de bloqueo residual fue de 11.5 por ciento para el grupo A y de 9.9 por ciento para el grupo B. Conclusión: La incidencia de bloqueo residual con el uso de relajantes de acción intermedia es baja, comparada con la reportada con los relajantes musculares de acción prolongada. El parámetro de valoración DBS 3.2 es mas específico para detectar la presencia de bloqueo residual, mientras que al utilizar la relación TOF T4/T1, se deben tener en cuenta valores mayores de 0.80 para descartar bloqueo residual debe ser utilizada preferiblemente en forma conjunta con el DBS